Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.50 |
| ▸ | MELK | Q14680 | 9/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.48 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.48 |
| ▸ | NUAK1 | O60285 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.48 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.48 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.48 |
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.48 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.48 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.48 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.43 |
| ▸ | KDR | P35968 | 7/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.43 |
| ▸ | FLT1 | P17948 | 2/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL851520 | 1.00 | AAK1 (0.50) | AAK1MELKCHEK1PRKAB2NUAK1 | |
| SCHEMBL30577752 | 1.00 | AAK1 (0.50) | AAK1MELKCHEK1PRKAB2NUAK1 | |
| SCHEMBL30577753 | 1.00 | AAK1 (0.50) | AAK1MELKCHEK1PRKAB2NUAK1 | |
| Acetic Acid SCHEMBL19283596 | 0.98 | AAK1 (0.49) | AAK1MELKCHEK1PRKAB2NUAK1 | |
| SCHEMBL19283556 | 0.97 | AAK1 (0.48) | AAK1MELKCHEK1PRKAB2NUAK1 | |
| Phosphoric Acid SCHEMBL19283570 | 0.97 | AAK1 (0.48) | AAK1MELKCHEK1PRKAB2NUAK1 | |
| Maleic Acid SCHEMBL19283594 | 0.96 | AAK1 (0.47) | AAK1MELKCHEK1PRKAB2NUAK1 | |
| SCHEMBL18825322 | 0.95 | AAK1 (0.47) | AAK1MELKCHEK1PRKAB2NUAK1 | |
| SCHEMBL19283636 | 0.95 | AAK1 (0.47) | AAK1MELKCHEK1PRKAB2NUAK1 | |
| Water SCHEMBL30195876 | 0.95 | AAK1 (0.46) | AAK1MELKCHEK1PRKAB2NUAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230088661-A1 | INHALABLE LIPOSOMAL SUSTAINED RELEASE COMPOSITION FOR USE IN TREATING PULMONARY DISEASES | INSPIRMED CORP (TW) | 2023-03-23 | — | — | US | claimed |
| CN-108718526-B | Crystal modification of nintedanib salt and process for producing the same | 赞蒂瓦有限合伙公司（CZ） | 2023-01-13 | — | — | CN | claimed |
| EP-3419964-B1 | CRYSTALLINE MODIFICATIONS OF METHYL (3Z)-3-{[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO} PHENYL)AMINO](PHENYL)METHYLIDENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE SALTS AND METHODS OF PREPARATION THEREOF | ZENTIVA KS (CZ) | 2022-06-22 | — | — | EP | claimed |
| EP-3643309-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2020-04-29 | — | — | EP | claimed |
| US-20190055197-A1 | CRYSTALLINE MODIFICATIONS OF METHYL (3Z)-3-{[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO}PHENYL)AMINO](PHENYL)METHYLIDENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE SALTS AND METHODS OF PREPARATION THEREOF | ZENTIVA K.S. (CZ) | 2019-02-21 | — | — | US | claimed |
| EP-3419964-A1 | CRYSTALLINE MODIFICATIONS OF METHYL (3Z)-3-{[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO} PHENYL)AMINO](PHENYL)METHYLIDENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE SALTS AND METHODS OF PREPARATION THEREOF | Zentiva, K.S. (CZ) | 2019-01-02 | — | — | EP | claimed |
| EP-2786765-B1 | Composition for combination therapy comprising an anti-C-met antibody and a FGFR inhibitor | SAMSUNG ELECTRONICS CO LTD (KR) | 2018-10-03 | — | — | EP | claimed |
| WO-2017144029-A1 | CRYSTALLINE MODIFICATIONS OF METHYL (3Z)-3-{[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO} PHENYL)AMINO](PHENYL)METHYLIDENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE SALTS AND METHODS OF PREPARATION THEREOF | ZENTIVA, K.S. (CZ) | 2017-08-31 | — | — | WO | claimed |
| US-20160136133-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-05-19 | — | — | US | claimed |
| EP-2878297-A1 | Medicaments for the treatment or prevention of fibrotic diseases | Boehringer Ingelheim International GmbH (DE) | 2015-06-03 | — | — | EP | claimed |
| US-20140296217-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-02 | — | — | US | claimed |
| WO-2012052757-A1 | TUMOUR PHENOTYPE PATIENT SELECTION METHOD | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | WO | claimed |
| EP-1527047-B1 | 3-Z- 1-(4-(N-((4-METHYL-PIPERAZIN-1-YL)-METHYLCARBONYL)-N-ME THYL-AMINO)-ANILINO)-1-PHENYL-METHYLENE -6-METHOXYCARBONYL-2 -INDOLINONE-MONOETHANESULPHONATE AND THE USE THEREOF AS A PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-03-28 | — | — | EP | claimed |
| EP-2384751-A1 | Medicaments for the treatment or prevention of fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-09 | — | — | EP | claimed |
| US-20100204211-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | claimed |
| JP-2008525370-A | — | — | 2008-07-17 | — | — | JP | claimed |
| EP-1830843-A2 | INDOLIDONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-09-12 | — | — | EP | claimed |
| US-20060142373-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | claimed |
| WO-2006067165-A2 | INDOLIDONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | WO | claimed |
| US-20250136580-A1 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-01 | — | — | US | disclosed |
| US-20240238279-A1 | COMPOSITIONS AND METHODS OF USING NINTEDANIB FOR TREATING OCULAR DISEASES WITH ABNORMAL NEOVASCULARIZATION | ADS THERAPEUTICS LLC | 2024-07-18 | — | — | US | disclosed |
| US-20240165078-A1 | THERAPEUTIC TARGETING OF RECEPTOR TYROSINE KINASE INHIBITOR-INDUCED ANDROGEN RECEPTOR PHOSPHORYLATION IN CANCER | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2024-05-23 | — | — | US | disclosed |
| EP-3732179-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING FIBROSIS | UNIV YALE (US) | 2024-05-01 | — | — | EP | disclosed |
| US-11951103-B2 | Pharmaceutical composition | KYOWA KIRIN CO., LTD. (JP) | 2024-04-09 | — | — | US | disclosed |
| US-11911379-B2 | Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization | ADS THERAPEUTICS LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240051920-A1 | AN IMPROVED HIGHLY EFFICIENT PROCESS FOR THE PREPARATION OF NINTEDANIB AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | BDR LIFESCIENCES PRIVATE LIMITED (IN) | 2024-02-15 | — | — | US | disclosed |
| EP-4281078-A1 | PHARMACEUTICAL COMBINATIONS OF SOS1 INHIBITORS FOR TREATING AND/OR PREVENTING CANCER | Lupin Limited (IN) | 2023-11-29 | — | — | EP | disclosed |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2023-11-23 | — | — | US | disclosed |
| EP-3302379-B1 | COMPOSITIONS AND METHODS FOR TREATING PTERYGIUM | CLOUDBREAK THERAPEUTICS LLC (US) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023183822-A1 | HEMATOPOIETIC LOSS OF Y CHROMOSOME LEADS TO CARDIAC FIBROSIS AND DYSFUNCTION AND IS ASSOCIATED WITH DEATH DUE TO HEART FAILURE | UNIVERSITY OF VIRGINA PATENT FOUNDATION (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-3784213-B1 | INHALABLE LIPOSOMAL SUSTAINED RELEASE COMPOSITION FOR USE IN TREATING PULMONARY DISEASES | INSPIRMED CORP (TW) | 2023-09-06 | — | — | EP | disclosed |
| US-20230256106-A1 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230181588-A1 | Compounds and Compositions for Treating Fibrosis | UNIV YALE (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230181582-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INJURIES ASSOCIATED WITH VIRAL INFECTIONS | Qx Therapeutics Inc. (US) | 2023-06-15 | — | — | US | disclosed |
| US-11660281-B2 | Compositions and methods of treating or preventing fibrotic lung diseases | YALE UNIVERSITY (US) | 2023-05-30 | — | — | US | disclosed |
| WO-2023091479-A1 | DETECTION AND TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | AmMax Bio, Inc. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230152330-A1 | DETECTION AND TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | AMMAX BIO INC (US) | 2023-05-18 | — | — | US | disclosed |
| WO-2023066881-A1 | INHIBITION OF MAP3K15 FOR TREATING AND PREVENTING DIABETES | ASTRAZENECA AB (SE) | 2023-04-27 | — | — | WO | disclosed |
| US-20230088661-A1 | INHALABLE LIPOSOMAL SUSTAINED RELEASE COMPOSITION FOR USE IN TREATING PULMONARY DISEASES | INSPIRMED CORP (TW) | 2023-03-23 | — | — | US | disclosed |
| EP-3710427-B1 | SYNTHESIS OF A 2-INDOLINONE DERIVATIVE KNOWN AS INTERMEDIATE FOR PREPARING NINTEDANIB | FERMION OY (FI) | 2023-03-08 | — | — | EP | disclosed |
| CN-108718526-B | Crystal modification of nintedanib salt and process for producing the same | 赞蒂瓦有限合伙公司（CZ） | 2023-01-13 | — | — | CN | disclosed |
| US-11534399-B2 | Inhalable liposomal sustained release composition for use in treating pulmonary diseases | INSPIRMED CORP. (TW) | 2022-12-27 | — | — | US | disclosed |
| EP-4098246-A1 | FORMULATION OF NINTEDANIB | Lotus Pharmaceutical Co., Ltd. (TW) | 2022-12-07 | — | — | EP | disclosed |
| US-11504373-B2 | Compounds and compositions for treating fibrosis | YALE UNIVERSITY (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220202816-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INJURIES ASSOCIATED WITH SARS-COV-2 INFECTIONS | Qx Therapeutics Inc. (US) | 2022-06-30 | — | — | US | disclosed |
| EP-4000634-A1 | MEDICINAL COMPOSITION COMPRISING TIVOZANIB | Kyowa Kirin Co., Ltd. (JP) | 2022-05-25 | — | — | EP | disclosed |
| US-20220125783-A1 | COMPOSITIONS AND METHODS OF USING NINTEDANIB FOR TREATING OCULAR DISEASES WITH ABNORMAL NEOVASCULARIZATION | ADS THERAPEUTICS LLC | 2022-04-28 | — | — | US | disclosed |
| US-11304947-B2 | Compositions and methods for treating lung injuries associated with SARS-COV-2 infections | Qx Therapeutics Inc. (US) | 2022-04-19 | — | — | US | disclosed |
| US-11261158-B2 | Synthesis of 2-indolinone derivatives | FERMION OY (FI) | 2022-03-01 | — | — | US | disclosed |
| US-11246864-B2 | Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization | ADS THERAPEUTICS LLC (US) | 2022-02-15 | — | — | US | disclosed |
| CN-111973596-B | Anti-pulmonary fibrosis composition with improved dissolution property | 深圳市泰力生物医药有限公司 | 2022-02-15 | — | — | CN | disclosed |
| US-20220023293-A1 | EZH2- FGFR INHIBITION IN CANCER | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis (NL) | 2022-01-27 | — | — | US | disclosed |
| US-20220000772-A1 | SPECIALLY FORMULATED COMPOSITIONS OF INHALED NINTEDANIB AND NINTEDANIB SALTS | AVALYN PHARMA INC. | 2022-01-06 | — | — | US | disclosed |
| US-20210361650-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INJURIES ASSOCIATED WITH SARS-COV-2 INFECTIONS | Qx Therapeutics Inc. (US) | 2021-11-25 | — | — | US | disclosed |
| EP-3898615-A1 | 7-((3,5-DIMETHOXYPHENYL)AMINO)QUINOXALINE DERIVATIVES AS FGFR INHIBITORS FOR TREATING CANCER | Array Biopharma, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| US-20210317107-A1 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-10-14 | — | — | US | disclosed |
| EP-3890782-A2 | EZH2- FGFR INHIBITION IN CANCER | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2021-10-13 | — | — | EP | disclosed |
| US-20210308042-A1 | COMPOSITIONS AND METHODS FOR TREATING PTERYGIUM RECURRENCE | CLOUDBREAK THERAPEUTICS, LLC | 2021-10-07 | — | — | US | disclosed |
| US-11123290-B2 | Specially formulated compositions of inhaled nintedanib and nintedanib salts | AVALYN PHARMA INC. (US) | 2021-09-21 | — | — | US | disclosed |
| EP-3860569-A1 | PHARMACEUTICAL FORMULATION | Cipla Limited (IN) | 2021-08-11 | — | — | EP | disclosed |
| EP-3841090-A1 | SPECIALLY FORMULATED COMPOSITIONS OF INHALED NINTEDANIB AND NINTEDANIB SALTS | Avalyn Pharma Inc. (US) | 2021-06-30 | — | — | EP | disclosed |
| US-20210145740-A1 | INHALABLE LIPOSOMAL SUSTAINED RELEASE COMPOSITION FOR USE IN TREATING PULMONARY DISEASES | INSPIRMED CORP. (TW) | 2021-05-20 | — | — | US | disclosed |
| US-10981896-B2 | Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-04-20 | — | — | US | disclosed |
| US-10980741-B2 | Compositions and methods for treating pterygium recurrence | CLOUDBREAK THERAPEUTICS, LLC (US) | 2021-04-20 | — | — | US | disclosed |
| EP-3784213-A1 | INHALABLE LIPOSOMAL SUSTAINED RELEASE COMPOSITION FOR USE IN TREATING PULMONARY DISEASES | TLC Biopharmaceuticals, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| US-20200390770-A1 | Compounds and Compositions for Treating Fibrosis | UNIV YALE (US) | 2020-12-17 | — | — | US | disclosed |
| EP-3740210-A1 | THERAPEUTIC TARGETING OF RECEPTOR TYROSINE KINASE INHIBITOR-INDUCED ANDROGEN RECEPTOR PHOSPHORYLATION IN CANCER | Indiana University Research and Technology Corporation (US) | 2020-11-25 | — | — | EP | disclosed |
| CN-111973596-A | Anti-pulmonary fibrosis composition with improved dissolution property | 深圳市泰力生物医药有限公司 | 2020-11-24 | — | — | CN | disclosed |
| US-20200345692-A1 | THERAPEUTIC TARGETING OF RECEPTOR TYROSINE KINASE INHIBITOR-INDUCED ANDROGEN RECEPTOR PHOSPHORYATION IN CANCER | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2020-11-05 | — | — | US | disclosed |
| EP-3732179-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING FIBROSIS | Yale University (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20200330435-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2020-10-22 | — | — | US | disclosed |
| US-20200299275-A1 | SYNTHESIS OF 2-INDOLINONE DERIVATIVES | FERMION OY (FI) | 2020-09-24 | — | — | US | disclosed |
| EP-3710427-A1 | SYNTHESIS OF A 2-INDOLINONE DERIVATIVE KNOWN AS INTERMEDIATE FOR PREPARING NINTEDANIB | Fermion Oy (FI) | 2020-09-23 | — | — | EP | disclosed |
| US-10772885-B2 | Composition for treating ocular diseases and methods of usage and making | REYOUNG (SUZHOU) BIOLOGY SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2020-09-15 | — | — | US | disclosed |
| EP-2229360-B1 | INDOLINONE DERIVATIVES AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INT (DE) | 2020-07-01 | — | — | EP | disclosed |
| WO-2020131674-A1 | 7-((3,5-DIMETHOXYPHENYL)AMINO)QUINOXALINE DERIVATIVES AS FGFR INHIBITORS FOR TREATING CANCER | ARRAY BIOPHARMA INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-10688092-B2 | Compositions and methods of using nintedanib for improving glaucoma surgery success | CLOUDBREAK THERAPEUTICS, LLC (US) | 2020-06-23 | — | — | US | disclosed |
| WO-2020117052-A2 | EZH2- FGFR INHIBITION IN CANCER | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis (NL) | 2020-06-11 | — | — | WO | disclosed |
| EP-3650040-A1 | VEGF INHIBITORS FOR USE FOR PREVENTING AND/OR TREATING ATOPIC DERMATITIS | Galderma Research & Development (FR) | 2020-05-13 | — | — | EP | disclosed |
| EP-3643309-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2020-04-29 | — | — | EP | disclosed |
| WO-2020079706-A1 | PHARMACEUTICAL FORMULATION | CIPLA LIMITED (IN) | 2020-04-23 | — | — | WO | disclosed |
| WO-2020041631-A1 | SPECIALLY FORMULATED COMPOSITIONS OF INHALED NINTEDANIB AND NINTEDANIB SALTS | AVALYN PHARMA INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| US-20200060968-A1 | SPECIALLY FORMULATED COMPOSITIONS OF INHALED NINTEDANIB AND NINTEDANIB SALTS | AVALYN PHARMA INC. (US) | 2020-02-27 | — | — | US | disclosed |
| US-20190290643-A1 | COMPOSITIONS AND METHODS OF USING NINTEDANIB FOR IMPROVING GLAUCOMA SURGERY SUCCESS | ADS THERAPEUTICS LLC | 2019-09-26 | — | — | US | disclosed |
| US-20190224194-A1 | COMPOSITION FOR TREATING OCULAR DISEASES AND METHODS OF USAGE AND MAKING | REYOUNG (SUZHOU) BIOLOGY SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2019-07-25 | — | — | US | disclosed |
| WO-2019143908-A1 | THERAPEUTIC TARGETING OF RECEPTOR TYROSINE KINASE INHIBITOR-INDUCED ANDROGEN RECEPTOR PHOSPHORYLATION IN CANCER | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-07-25 | — | — | WO | disclosed |
| EP-3513809-A1 | MEDICINAL COMPOSITION | Kyowa Hakko Kirin Co., Ltd. (JP) | 2019-07-24 | — | — | EP | disclosed |
| US-10335408-B2 | Compositions and methods of using nintedanib for improving glaucoma surgery success | CLOUDBREAK THERAPEUTICS, LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190110984-A1 | COMPOSITIONS AND METHODS FOR TREATING PTERYGIUM RECURRENCE | CLOUDBREAK THERAPEUTICS, LLC | 2019-04-18 | — | — | US | disclosed |
| US-20190055197-A1 | CRYSTALLINE MODIFICATIONS OF METHYL (3Z)-3-{[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO}PHENYL)AMINO](PHENYL)METHYLIDENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE SALTS AND METHODS OF PREPARATION THEREOF | ZENTIVA K.S. (CZ) | 2019-02-21 | — | — | US | disclosed |
| US-20190055197-A1 | CRYSTALLINE MODIFICATIONS OF METHYL (3Z)-3-{[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO}PHENYL)AMINO](PHENYL)METHYLIDENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE SALTS AND METHODS OF PREPARATION THEREOF | ZENTIVA K.S. (CZ) | 2019-02-21 | — | — | US | disclosed |
| US-20190038600-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DEISEASES | BOEHRINGER INGELHEIM INT (DE) | 2019-02-07 | — | — | US | disclosed |
| EP-3419964-A1 | CRYSTALLINE MODIFICATIONS OF METHYL (3Z)-3-{[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO} PHENYL)AMINO](PHENYL)METHYLIDENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE SALTS AND METHODS OF PREPARATION THEREOF | Zentiva, K.S. (CZ) | 2019-01-02 | — | — | EP | disclosed |
| EP-3419964-A1 | CRYSTALLINE MODIFICATIONS OF METHYL (3Z)-3-{[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO} PHENYL)AMINO](PHENYL)METHYLIDENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE SALTS AND METHODS OF PREPARATION THEREOF | Zentiva, K.S. (CZ) | 2019-01-02 | — | — | EP | disclosed |
| US-10154990-B2 | Medicaments for the treatment or prevention of fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-12-18 | — | — | US | disclosed |
| EP-3412288-A1 | VEGF INHIBITORS FOR USE FOR PREVENTING AND/OR TREATING ACNE | Galderma Research & Development (FR) | 2018-12-12 | — | — | EP | disclosed |
| US-10149819-B2 | Compositions and methods for treating hyperemia | CLOUDBREAK THERAPEUTICS, LLC (US) | 2018-12-11 | — | — | US | disclosed |
| US-10149820-B2 | Compositions and methods for treating pterygium | CLOUDBREAK THERAPEUTICS, LLC (US) | 2018-12-11 | — | — | US | disclosed |
| US-10125122-B2 | Method for preparing methyl (Z)-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene)oxindole-6-carboxylate (intedanib, nintedanib) | ZENTIVA K.S. (CZ) | 2018-11-13 | — | — | US | disclosed |
| EP-2786765-B1 | Composition for combination therapy comprising an anti-C-met antibody and a FGFR inhibitor | SAMSUNG ELECTRONICS CO LTD (KR) | 2018-10-03 | — | — | EP | disclosed |
| US-20180271781-A1 | COMPOSITIONS AND METHODS FOR TREATING PTERYGIUM | CLOUDBREAK THERAPEUTICS, LLC | 2018-09-27 | — | — | US | disclosed |
| US-20180271780-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPEREMIA | CLOUDBREAK THERAPEUTICS, LLC | 2018-09-27 | — | — | US | disclosed |
| WO-2018160967-A1 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-09-07 | — | — | WO | disclosed |
| US-9987223-B2 | Compositions and methods for treating pterygium | CLOUDBREAK THERAPEUTICS, LLC (US) | 2018-06-05 | — | — | US | disclosed |
| US-9980901-B2 | Compositions and methods for treating pterygium | CLOUDBREAK THERAPEUTICS, LLC (US) | 2018-05-29 | — | — | US | disclosed |
| EP-2229359-B1 | PROCESS FOR THE MANUFACTURE OF AN INDOLINONE DERIVATIVE | BOEHRINGER INGELHEIM INT (DE) | 2017-11-29 | — | — | EP | disclosed |
| WO-2017144029-A1 | CRYSTALLINE MODIFICATIONS OF METHYL (3Z)-3-{[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO} PHENYL)AMINO](PHENYL)METHYLIDENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE SALTS AND METHODS OF PREPARATION THEREOF | ZENTIVA, K.S. (CZ) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017144029-A1 | CRYSTALLINE MODIFICATIONS OF METHYL (3Z)-3-{[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO} PHENYL)AMINO](PHENYL)METHYLIDENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE SALTS AND METHODS OF PREPARATION THEREOF | ZENTIVA, K.S. (CZ) | 2017-08-31 | — | — | WO | disclosed |
| US-20170209368-A1 | COMPOSITIONS AND METHODS FOR TREATING PTERYGIUM | CLOUDBREAK THERAPEUTICS, LLC | 2017-07-27 | — | — | US | disclosed |
| US-9359433-B2 | FGF modulation of in vivo antibody production and humoral immunity | BUSH ANDREW B (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160136133-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-05-19 | — | — | US | disclosed |
| EP-2994130-A1 | FGF MODULATION OF IN VIVO ANTIBODY PRODUCTION AND HUMORAL IMMUNITY | Bush, Andrew B. (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20160060334-A1 | FGF MODULATION OF IN VIVO ANTIBODY PRODUCTION AND HUMORAL IMMUNITY | BUSH ANDREW B (US) | 2016-03-03 | — | — | US | disclosed |
| US-9226960-B2 | FGF modulation of in vivo antibody production and humoral immunity | BUSH ANDREW B (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150374767-A1 | Treatment of Cancer | VIRTTU BIOLOGICS LIMITED (GB) | 2015-12-31 | — | — | US | disclosed |
| EP-2878297-A1 | Medicaments for the treatment or prevention of fibrotic diseases | Boehringer Ingelheim International GmbH (DE) | 2015-06-03 | — | — | EP | disclosed |
| WO-2015038710-A1 | METHODS FOR DIAGNOSING AND TREATING INTRAHEPATIC CHOLANGIOCARCINOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2015-03-19 | — | — | WO | disclosed |
| WO-2014182277-A1 | FGF MODULATION OF IN VIVO ANTIBODY PRODUCTION AND HUMORAL IMMUNITY | BUSH ANDREW B (US) | 2014-11-13 | — | — | WO | disclosed |
| EP-2786765-A2 | Composition for combination therapy comprising an anti-C-met antibody and a FGFR inhibitor | Samsung Electronics Co., Ltd. (KR) | 2014-10-08 | — | — | EP | disclosed |
| US-20140296217-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-02 | — | — | US | disclosed |
| US-20130236483-A1 | FGF MODULATION OF IN VIVO ANTIBODY PRODUCTION AND HUMORAL IMMUNITY | BUSH ANDREW B (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2012068441-A2 | INTEDANIB SALTS AND SOLID STATE FORMS THEREOF | RATIOPHARM GMBH (DE) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012051663-A1 | ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2012-04-26 | — | — | WO | disclosed |
| EP-1527047-B1 | 3-Z- 1-(4-(N-((4-METHYL-PIPERAZIN-1-YL)-METHYLCARBONYL)-N-ME THYL-AMINO)-ANILINO)-1-PHENYL-METHYLENE -6-METHOXYCARBONYL-2 -INDOLINONE-MONOETHANESULPHONATE AND THE USE THEREOF AS A PHARMACEUTICAL COMPOSITION | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-03-28 | — | — | EP | disclosed |
| EP-2384751-A1 | Medicaments for the treatment or prevention of fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-09 | — | — | EP | disclosed |
| US-20100204211-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | disclosed |
| EP-1830843-A2 | INDOLIDONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-09-12 | — | — | EP | disclosed |
| US-20060142373-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
| US-20060142373-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
| WO-2006067165-A2 | INDOLIDONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (32 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374767-A1 | Treatment of Cancer | EGFR, ERBB2, MET | AAK1 1005/4885MELK 898/4885CHEK1 152/4885 |
| US-20230256106-A1 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | TIE1, TEK, KDR | AAK1 3766/4885MELK 392/4885CHEK1 4454/4885 |
| US-20100204211-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | AAK1 3831/4885MELK 2222/4885CHEK1 4470/4885 |
| US-20220000772-A1 | SPECIALLY FORMULATED COMPOSITIONS OF INHALED NINTEDANIB AND NINTEDANIB SALTS | FGF2, FIBP, REN | AAK1 1823/4885MELK 745/4885CHEK1 3486/4885 |
| US-20060142373-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | MMP1, COL1A1, FOXM1 | AAK1 3831/4885MELK 2222/4885CHEK1 4470/4885 |
| US-11261158-B2 | Synthesis of 2-indolinone derivatives | AZI2, AANAT, IDO1 | AAK1 349/4885MELK 1022/4885CHEK1 1568/4885 |
| US-20200330435-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | AAK1 3831/4885MELK 2222/4885CHEK1 4470/4885 |
| US-11123290-B2 | Specially formulated compositions of inhaled nintedanib and nintedanib salts | FGF2, FIBP, REN | AAK1 1823/4885MELK 745/4885CHEK1 3486/4885 |
| US-11304947-B2 | Compositions and methods for treating lung injuries associated with SARS-COV-2 infections | MAP3K3, MAP3K2, MAP3K13 | AAK1 252/4885MELK 946/4885CHEK1 305/4885 |
| US-20160136133-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | AAK1 3831/4885MELK 2222/4885CHEK1 4470/4885 |
| US-20200060968-A1 | SPECIALLY FORMULATED COMPOSITIONS OF INHALED NINTEDANIB AND NINTEDANIB SALTS | FGF2, FIBP, REN | AAK1 1823/4885MELK 745/4885CHEK1 3486/4885 |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, SMAD3 | AAK1 4173/4885MELK 1782/4885CHEK1 4444/4885 |
| US-10154990-B2 | Medicaments for the treatment or prevention of fibrotic diseases | MMP1, COL1A1, FOXM1 | AAK1 3831/4885MELK 2222/4885CHEK1 4470/4885 |
| US-20130236483-A1 | FGF MODULATION OF IN VIVO ANTIBODY PRODUCTION AND HUMORAL IMMUNITY | FGF2, FGF1, FGFR2 | AAK1 1870/4885MELK 230/4885CHEK1 4497/4885 |
| US-11504373-B2 | Compounds and compositions for treating fibrosis | DUSP5, DUSP15, LPCAT3 | AAK1 2692/4885MELK 2273/4885CHEK1 4084/4885 |
| US-11660281-B2 | Compositions and methods of treating or preventing fibrotic lung diseases | ADRB3, ADRB1, TGFBR1 | AAK1 3584/4885MELK 3008/4885CHEK1 3743/4885 |
| US-20140296217-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | AAK1 3831/4885MELK 2222/4885CHEK1 4470/4885 |
| US-20160060334-A1 | FGF MODULATION OF IN VIVO ANTIBODY PRODUCTION AND HUMORAL IMMUNITY | FGF2, FGF1, FGFR2 | AAK1 1870/4885MELK 230/4885CHEK1 4497/4885 |
| US-20230181588-A1 | Compounds and Compositions for Treating Fibrosis | DUSP5, DUSP15, DUSP26 | AAK1 2746/4885MELK 2667/4885CHEK1 3915/4885 |
| US-20220202816-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INJURIES ASSOCIATED WITH SARS-COV-2 INFECTIONS | MAP3K3, MAP3K2, MAP3K13 | AAK1 252/4885MELK 946/4885CHEK1 305/4885 |
| US-20190038600-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DEISEASES | MMP1, COL1A1, IDO1 | AAK1 3733/4885MELK 3403/4885CHEK1 4560/4885 |
| US-20210317107-A1 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | MELK, HIPK1, HIPK3 | AAK1 65/4885MELK 1/4885CHEK1 252/4885 |
| US-20200390770-A1 | Compounds and Compositions for Treating Fibrosis | DUSP5, DUSP15, LPCAT3 | AAK1 2692/4885MELK 2273/4885CHEK1 4084/4885 |
| US-20230181582-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INJURIES ASSOCIATED WITH VIRAL INFECTIONS | MAP3K3, MAP3K2, MAP3K21 | AAK1 52/4885MELK 553/4885CHEK1 599/4885 |
| US-20200299275-A1 | SYNTHESIS OF 2-INDOLINONE DERIVATIVES | AZI2, AANAT, IDO1 | AAK1 349/4885MELK 1022/4885CHEK1 1568/4885 |
| US-20190055197-A1 | CRYSTALLINE MODIFICATIONS OF METHYL (3Z)-3-{[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO}PHENYL)AMINO](PHENYL)METHYLIDENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE SALTS AND METHODS OF PREPARATION THEREOF | PCMT1, DDC, TPMT | AAK1 1965/4885MELK 1491/4885CHEK1 2733/4885 |
| US-11951103-B2 | Pharmaceutical composition | EGFR, VEGFA, KDR | AAK1 2903/4885MELK 3094/4885CHEK1 3954/4885 |
| US-10125122-B2 | Method for preparing methyl (Z)-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene)oxindole-6-carboxylate (intedanib, nintedanib) | ALK, ACVR2B, NAT1 | AAK1 1986/4885MELK 1886/4885CHEK1 3098/4885 |
| US-10981896-B2 | Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase | MELK, HIPK1, HIPK3 | AAK1 88/4885MELK 1/4885CHEK1 310/4885 |
| US-20210361650-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INJURIES ASSOCIATED WITH SARS-COV-2 INFECTIONS | MAP3K3, MAP3K2, MAP3K13 | AAK1 252/4885MELK 946/4885CHEK1 305/4885 |
| US-20240051920-A1 | AN IMPROVED HIGHLY EFFICIENT PROCESS FOR THE PREPARATION OF NINTEDANIB AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | JAK1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, INMT | AAK1 1461/4885MELK 640/4885CHEK1 3359/4885 |
| US-20250136580-A1 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | MELK, HIPK1, HIPK3 | AAK1 65/4885MELK 1/4885CHEK1 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.